New scan could spot prostate cancer that hides from standard tests

NCT ID NCT06062745

Recruiting now Diagnosis Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests whether a special PET scan using 18F-fluciclovine can find prostate cancer that doesn't show up well on standard PSMA scans. The study will include 30 men with advanced prostate cancer that either has low PSMA levels or has changed into a more aggressive neuroendocrine type. Researchers will compare the number of cancer spots seen on this new scan to those seen on standard scans to see if it can better detect hard-to-find disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-fluciclovine (a radioactive tracer used in PET scans)
What this could lead to: If successful, this could improve detection of aggressive prostate cancers that are missed by current PSMA-PET scans, helping guide better treatment decisions.
What could go wrong: This is a very early pilot study with only 30 participants. It is testing imaging, not treatment, so it won't directly improve outcomes. The tracer may not reliably distinguish cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate carcinoma prostate small cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PROSTATE CANCER METASTATIC PROSTATE CANCER METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA

Contacts and locations

Locations

Brigham and Womens Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.